Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis

被引:53
作者
Jia, HY
Lohr, M
Jezequel, S
Davis, D
Shaikh, S
Selwood, D
Zachary, I
机构
[1] UCL, Rayne Inst, Dept Med, London WC1E 6JJ, England
[2] UCL, Rayne Inst, Wolfson Inst Biomed Res, London WC1E 6JJ, England
[3] UCL, Rayne Inst, Ark Therapeut Ltd, London WC1E 6JJ, England
关键词
VEGF; KDR; ERK; basic FGF;
D O I
10.1006/bbrc.2001.4790
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Previous findings suggest that both the Tat polypeptide encoded by HIV-1 and Tat-derived peptides can induce angiogenesis via activation of the KDR receptor for Vascular Endothelial Growth Factor (VEGF), We identified 20 amino acids and 12 amino acid peptides corresponding to the cysteine-rich and basic domains of HIV-1 Tat which inhibited I-125-VEGF(165) binding to KDR and neuropilin-1 (NP-1) receptors in endothelial cells. Cysteine-rich and basic Tat peptides inhibited VEGF-induced ERK activation and mitogenesis in endothelial cells, and inhibited angiogenesis in vitro at concentrations similar to those which inhibited VEGF receptor binding. These peptides also inhibited proliferation, angiogenesis, and ERK activation induced by basic fibroblast growth factor with similar potency and efficacy. Surprisingly, we found that both cysteine-rich and basic domain Tat peptides strikingly induced apoptosis in endothelial cells, independent of their effects on VEGF and bFGF. Furthermore, we found no evidence for direct biological effects of recombinant Tat on VEGF receptor binding, ERK activation, endothelial cell survival, or mitogenesis. These findings demonstrate novel properties of Tat-derived peptides and indicate that their major effect in endothelial cells is apoptosis independent of specific inhibition of VEGF receptor activation. (C) 2001 Academic Press.
引用
收藏
页码:469 / 479
页数:11
相关论文
共 40 条
[31]   Vascular endothelial growth factor (VEGF) and its receptors [J].
Neufeld, G ;
Cohen, T ;
Gengrinovitch, S ;
Poltorak, Z .
FASEB JOURNAL, 1999, 13 (01) :9-22
[32]   Mechanisms of angiogenesis [J].
Risau, W .
NATURE, 1997, 386 (6626) :671-674
[33]   PATTERNS OF EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) AND VEGF RECEPTORS IN MICE SUGGEST A ROLE IN HORMONALLY REGULATED ANGIOGENESIS [J].
SHWEIKI, D ;
ITIN, A ;
NEUFELD, G ;
GITAYGOREN, H ;
KESHET, E .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (05) :2235-2243
[34]   Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor [J].
Soker, S ;
Takashima, S ;
Miao, HQ ;
Neufeld, G ;
Klagsbrun, M .
CELL, 1998, 92 (06) :735-745
[35]   Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF(165) via its exon 7-encoded domain [J].
Soker, S ;
Fidder, H ;
Neufeld, G ;
Klagsbrun, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (10) :5761-5767
[36]   BASIC FIBROBLAST GROWTH-FACTOR UP-REGULATES THE EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IN VASCULAR SMOOTH-MUSCLE CELLS - SYNERGISTIC INTERACTION WITH HYPOXIA [J].
STAVRI, GT ;
ZACHARY, IC ;
BASKERVILLE, PA ;
MARTIN, JF ;
ERUSALIMSKY, JD .
CIRCULATION, 1995, 92 (01) :11-14
[37]  
vanderZee R, 1997, CIRCULATION, V95, P1030
[38]  
WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
[39]   Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase [J].
Wheeler-Jones, C ;
Abu-Ghazaleh, R ;
Cospedal, R ;
Houliston, RA ;
Martin, J ;
Zachary, I .
FEBS LETTERS, 1997, 420 (01) :28-32
[40]   Vascular protection - A novel nonangiogenic cardiovascular role for vascular endothelial growth factor [J].
Zachary, I ;
Mathur, A ;
Yla-Herttuala, S ;
Martin, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (06) :1512-1520